Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Net Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Net Margin for 9 consecutive years, with 780.69% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 55475.0% to 780.69% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55.36% through Dec 2025, down 3102.0% year-over-year, with the annual reading at 342.96% for FY2025, 18014.0% down from the prior year.
  • Net Margin for Q4 2025 was 780.69% at Marker Therapeutics, up from 162.11% in the prior quarter.
  • The five-year high for Net Margin was 826.43% in Q4 2023, with the low at 3413.91% in Q3 2023.
  • Average Net Margin over 4 years is 438.27%, with a median of 140.97% recorded in 2025.
  • The sharpest move saw Net Margin tumbled -329457bps in 2023, then soared 329406bps in 2024.
  • Over 4 years, Net Margin stood at 107.1% in 2022, then skyrocketed by 872bps to 826.43% in 2023, then tumbled by -73bps to 225.94% in 2024, then surged by 246bps to 780.69% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 780.69%, 162.11%, and 479.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.